Insider · CIK 0001920545

Bodenstedt Matthias

Reports to the SEC for 1 company · ZUG

sec.gov

Transactions

Companies

Filings

CIK

0001920545

Forms 4 and 5

Insider transactions

24 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-06-22	MLTXMoonLake ImmunotherapeuticsS Sale	Chief Financial Officer	SSale	−39.1K sh	$22.04	−$862K	1,115,435
2026-06-18	MLTXMoonLake ImmunotherapeuticsS Sale	Chief Financial Officer	SSale	−2,794 sh	$19.60	−$54.8K	1,154,555
2026-06-17	MLTXMoonLake ImmunotherapeuticsS Sale	Chief Financial Officer	SSale	−15.1K sh	$19.68	−$297K	1,157,349
2026-05-11	MLTXMoonLake ImmunotherapeuticsS Sale	Chief Financial Officer	SSale	−13.7K sh	$20.02	−$273K	1,172,431
2026-04-14	MLTXMoonLake ImmunotherapeuticsS Sale	Chief Financial Officer	SSale	−2,426 sh	$19.56	−$47.5K	1,186,084
2026-04-10	MLTXMoonLake ImmunotherapeuticsS Sale	Chief Financial Officer	SSale	−1,925 sh	$19.51	−$37.6K	1,188,510
2026-04-09	MLTXMoonLake ImmunotherapeuticsS Sale	Chief Financial Officer	SSale	−85.9K sh	$18.94	−$1.63M	1,190,435
2026-01-07	MLTXMoonLake ImmunotherapeuticsA Award	Chief Financial Officer	AAward	+354K sh	—	—	1,276,305
2025-12-19	MLTXMoonLake ImmunotherapeuticsC Conversion	Chief Financial Officer	CConversion	+294K sh	—	—	922,009
2025-12-19	MLTXMoonLake ImmunotherapeuticsD Disposition to Issuer	Chief Financial Officer	DDisposition to Issuer	−294K sh	—	—	0
2025-12-19	MLTXMoonLake Immunotherapeutics · Common shares, par value CHF 0.10 per share, of MoonLake AGC Conversion	Chief Financial Officer	CConversion	−8,754 sh	—	—	0
2025-10-08	MLTXMoonLake ImmunotherapeuticsP Purchase	Chief Financial Officer	PPurchase	+10.9K sh	$9.09	+$98.8K	627,536
2025-02-27	MLTXMoonLake ImmunotherapeuticsA Award	Chief Financial Officer	AAward	+95.8K sh	—	—	616,666
2023-12-20	MLTXMoonLake ImmunotherapeuticsS Sale	Chief Financial Officer	SSale	−5,264 sh	$58.34	−$307K	520,903
2023-12-19	MLTXMoonLake ImmunotherapeuticsS Sale	Chief Financial Officer	SSale	−94.7K sh	$59.22	−$5.61M	526,167
2023-10-01	MLTXMoonLake ImmunotherapeuticsC Conversion	Chief Financial Officer	CConversion	+63K sh	—	—	620,903
2023-10-01	MLTXMoonLake ImmunotherapeuticsD Disposition to Issuer	Chief Financial Officer	DDisposition to Issuer	−63K sh	—	—	294,473
2023-10-01	MLTXMoonLake Immunotherapeutics · Common shares, par value CHF 0.10 per share, of MoonLake AGC Conversion	Chief Financial Officer	CConversion	−1,872 sh	—	—	8,754
2023-04-05	MLTXMoonLake ImmunotherapeuticsC Conversion	Chief Financial Officer	CConversion	+411K sh	—	—	410,796
2023-04-05	MLTXMoonLake ImmunotherapeuticsD Disposition to Issuer	Chief Financial Officer	DDisposition to Issuer	−411K sh	—	—	0
2023-04-05	MLTXMoonLake ImmunotherapeuticsC Conversion	Chief Financial Officer	CConversion	+147K sh	—	—	557,931
2023-04-05	MLTXMoonLake ImmunotherapeuticsD Disposition to Issuer	Chief Financial Officer	DDisposition to Issuer	−147K sh	—	—	357,445
2023-04-05	MLTXMoonLake Immunotherapeutics · Common shares, par value CHF 0.10 per share, of MoonLake AGC Conversion	Chief Financial Officer	CConversion	−12.2K sh	—	—	0
2023-04-05	MLTXMoonLake Immunotherapeutics · Common shares, par value CHF 0.10 per share, of MoonLake AGC Conversion	Chief Financial Officer	CConversion	−4,374 sh	—	—	10,626

Recent filings

Accepted (ET)
Jun 234
Bodenstedt Matthias0001213900-26-071075
SEC(opens sec.gov)
Jun 184
Bodenstedt Matthias0001213900-26-070259
SEC(opens sec.gov)
May 134
Bodenstedt Matthias0001213900-26-055799
SEC(opens sec.gov)
Apr 164
Bodenstedt Matthias0001213900-26-044642
SEC(opens sec.gov)
Apr 104
Bodenstedt Matthias0001213900-26-042629
SEC(opens sec.gov)
Jan 94
Bodenstedt Matthias0001213900-26-002907
SEC(opens sec.gov)
Dec 224
Bodenstedt Matthias0001213900-25-124519
SEC(opens sec.gov)
Oct 94
Bodenstedt Matthias0001213900-25-097594
SEC(opens sec.gov)
Mar 34
Bodenstedt Matthias0001213900-25-019672
SEC(opens sec.gov)
Dec 214
Bodenstedt Matthias0001213900-23-097671
SEC(opens sec.gov)
Oct 34
Bodenstedt Matthias0001013762-23-001300
SEC(opens sec.gov)
Apr 74
Bodenstedt Matthias0001213900-23-028294
SEC(opens sec.gov)

Companies

MoonLake ImmunotherapeuticsChief Financial OfficerMLTX

Address

C/O MOONLAKE IMMUNOTHERAPEUTICS DORFSTRASSE 29

ZUG, 6300